NOVO NORDISK Forum: Community User: 123abc

So schlecht sind die Zahlen jetzt aber auch nicht oder

Übel!

Fällt aber gerade wie ein Messer sieh Tradegate

01 Feb 2018 07:30 CETNovo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) Reported sales were broadly unchanged at DKK 112 billion (2% growth in local currencies) Sales within diabetes care and obesity increased by 4% to DKK 92.9 billion (7% in local currencies). Sales of Tresiba® increased by 81% to DKK 7.3 billion (85% in local currencies).Sales of Victoza® increased by 16% to DKK 23.2 billion (18% in local currencies).Sales of Saxenda® increased by 62% to DKK 2.6 billion (64% in local currencies) Sales within biopharmaceuticals declined by 18% to DKK 18.8 billion (16% in local currencies), reflecting the impact in the USA from the introduction of a generic version of the hormone replacement therapy product Vagifem® and a rebate adjustment for growth hormone in Q1 2016. Sales within haemophilia were broadly unchanged (2% growth in local currencies). Sales within International Operations increased by 2% in Danish kroner (5% in local currencies) driven by sales growth in all business regions measured in local currencies. Sales within North America Operations decreased by 2% in Danish kroner and were unchanged in local currencies, reflecting the non-recurring effects in biopharmaceuticals impacting growth negatively by 4 percentage points. Operating profit increased by 1% reported in Danish kroner and by 5% in local currencies to DKK 49.0 billion. Net profit increased by 1% to DKK 38.1 billion. Diluted earnings per share increased by 3% to DKK 15.39. In December, Novo Nordisk received the US Food and Drug Administration (FDA) approval of Ozempic®(semaglutide) for treatment of people with type 2 diabetes and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) recommending marketing authorisation for Ozempic®. Ozempic® will to be launched in the USA next week. Chairman of the Board of Directors Göran Ando has decided not to seek re-election at the Annual General Meeting in March 2018. The Board of Directors proposes current member of the Board of Directors Helge Lund to be elected as chairman of the Board of Directors. As per 15 February 2018, Karsten Munk Knudsen, currently senior vice president of Corporate Finance, will succeed Jesper Brandgaard as chief financial officer. Jesper Brandgaard will continue as executive vice president responsible for Biopharm and Legal Affairs. For 2018, sales growth is expected to be 2-5% measured in local currencies and operating profit growth is expected to be 1-5%. Sales growth reported in Danish kroner is expected to be 7 percentage points lower than in local currencies, reflecting the significant depreciation of the US dollar and related currencies versus the Danish krone. Likewise, reported operating profit growth is expected to be 10 percentage points lower. At the Annual General Meeting on 22 March 2018, the Board of Directors will propose a final dividend of DKK 4.85 for 2017 per share of DKK 0.20. The expected total dividend for 2017 of DKK 7.85 per share, of which DKK 3.00 per share was paid as interim dividend in August 2017, corresponds to an increase of 3% compared to 2016. The Board of Directors furthermore intends to initiate a new 12-month share repurchase programme of up to DKK 14 billion. Lars Fruergaard Jørgensen, president and CEO: "I am pleased that we delivered on our plans for 2017 and we are continuing to build a platform for sustainable growth. The approval of Ozempic® in the USA was the culmination of a year in which we achieved important product approvals and label updates. In 2018, we will focus on the global launch of Ozempic® and pursue the full value potential of our strong product portfolio in what continues to be a competitive environment."

Ich bin auch gespannt !

@Coe1: Schau einfach mal auf https://www.novonordisk.com/investors.html und klicke dort auf "Calendar"

Was ist morgen?

Bin mal auf morgen gespannt

Na Ablynx geht mal an Sanofi..

Scroll doch einfach ein bisschen zurück

@Huawei: und in welchem Zeitraum?

Ich habe in eine dicke Glaskugel geschaut und habe 60 gesehen.

@BRookie, schon klar, wachsende Bevölkerung, gestiegende Lebensverhältnisse, mehr ungesunder Konsum, nicht erschlossene Länder/Regionen usw. Aber NN ist nicht alleine, Patente laufen aus, Gernika Produkte sind billiger, auch in diesen Ländern wird die Preisgestaltung eine Rolle spielen, es gibt Regionen die haben eine nicht so tolle Krankenversicherung wie wir! ABER NN ist ein tolles Unternehmen den ich weiterhin treu bleibe jedoch muss NN schauen wir Wachstum generieren können aus den jetzigen Portfolio wird es sehr werden! Meine Meinung!

@Kimbim Ich bin der Meinung Novo kann noch gut wachsen. Es gibt noch viele Regionen auf der Erde, wo die medizinische Versorgung nicht so gut ist wie in der westlichen Welt. Im asiatischen Raum geht es erst los mit dem Wirtschadtswachstum und dann kommt auch der Konsum. Es gibt nach wie vor viele Leutr, die Diabetis haben, es aber gar nicht wissen.

https://www.fool.de/2018/01/19/risikoanalyse-novo-nordisk-lohnt-sich-die-aktie-noch/ Nicht schlecht erklärt

Wenn die Übernahme klappt sehe ich auch min die 60! Wenn nicht, wird es schwieriger, NN muss eine Übernahme machen damit das Portfolio wächst und das Wachstum wieder Sprit im Tank. Das eigene Portfolio, der Preisdruck und die nachmacher Produkte werden wohl für die 60 nicht reichen! Bin aber guter Dinge bei NN